Page 2 - Best Online Consultation with Oncologist doctors: TOP 87 doctors

Prof. Şeref Kömürcü is an ECFMG and ESMO-certified medical and breast oncologist with over 20 years of experience. He specializes in solid cancer, breast cancer, colorectal and lung cancer treatment and has held teaching and scientific positions throughout his career. He is a member of several professional organizations.

Prof. Yeşim (Yesim) Yıldırım — Medical Oncologist at Anadolu Medical Center (since 2011). ESMO-certified specialist, Professor since 2021, author of 80+ scientific publications. Trained at top centers — Rambam (Israel) and Mount Vernon (UK). Treats breast, lung, and gastrointestinal (GI) cancers, as well as melanoma and sarcomas; uses immunotherapy and targeted therapy.

Why patients choose Dr. Yeşim Yıldırım:

• 20+ years of clinical practice; Professor of Medical Oncology since 2021.
• 80+ peer-reviewed publications in tumor biology, immunotherapy, and targeted therapy — treatment plans are based on up-to-date evidence.
• ESMO certification — from Europe’s leading oncology society — confirms high qualification and continuous training to international standards.

Dr. Suleyman Hilmi Aksoy was born in 1974. He graduated from Istanbul University Çapa School of Medicine in 1998. He completed his residency in Radiodiagnostics and Interventional Radiology at Cerrahpaşa School of Medicine in 2002.

He has given oral and written presentations at 13 local and international congresses. Dr. Aksoy specializes in Diagnostic Radiology, Teleradiology, and Interventional Radiology. He has made important contributions in these areas.

He has worked at Hisar Intercontinental Hospital, Merzifon Air Hospital, Istanbul Emar Center, and Haseki Training and Research Hospital. Dr. Aksoy is dedicated to improving radiological practices.

Known Expertise 

Medical Oncologist 

Academic Position 

Senior Lecturer 

Education

Bar-Ilan University, Israel / Computational Biology 

Israeli Society for Health-Tech / Fellowship by IMA/ Innovation and Entrepreneurship in Medicine and Health-Tech 

Sheba Medical Center and Bar-Ilan University, Israel/ Genomics and Biomedical Informatics 

Semmelweis University/Doctor of Medicine 

Training and Specialization 

Clinical observership in acute oncology, early phase clinical trials and lung cancer/ Guy's and St. Thomas hospital, London, England 

Leader Shift, Executive Development Program, Tel-Aviv Sourasky Medical Center 

Fellowship Program in Innovation and Entrepreneurship in Medicine and Health-Tech 

Resident, Medical Oncology, TASMC, Israel 

6th year medical school rotations, Kaplan Medical Center, Israel 

Rotation, intensive care unit and pulmonology, Stony Brook hospital, NY, US 

Clinical Experience 

Leader of the TASMC oncology project of PSIFAS, the Israeli National Genomic Medicine Initiative 

PI for study initiator trial: T-Cell Repertoire sequencing as clinical efficacy tool for pembrolizumab (with platinum based chemotherapy) in advanced NSCLC. 

PI for study initiator trial: T-cell repertoire sequencing as a clinically efficacy tool for neoadjuvant immunotherapy plus platinum-doublet chemotherapy for resectable NSCLC. 

Representative of the National Medical Association for the National Council for the Prevention, Diagnosis and Treatment of Malignant Diseases, as well as head of the oncology field, Leumit HMO 

Consultant on drugs and operations in the field of oncology, Leumit HMO 

Member of the Helsinki Committee for Clinical Studies, TASMC 

Primary investigator (PI) in pharmaceutical phases I&III clinical trials Head of oncology day-care service, TASMC, Israel 

Molecular Tumor Board (MTB) moderator of the Israeli Lung Cancer Society 

NGS interpretation clinic alongside head of pathology, TASMC, Israel 

PI for study initiator trial: Genomic Variant of BCL-2 as a Novel Predictor of Response to Paclitaxel, TASMC, Israel 

Medical oncology clinic in the field of lung and breast cancer, TASMC, Israel

Leading sub-investigator (SI) in many phase I-III clinical trials in oncology, including intra-tumoral injections (mRNA, viruses and NO), TASMC, Israel 

Courses 

Good Clinical Practice ICH GCP R2 & Israeli MOH Guidelines Updated Course 

Point-of-Care Ultrasound course, Israeli Medical Association 

GCP training Bioforum 

GCP training Bioforum

Investigator Site Personnel ICH GCP Training Certificate - TransCelerate BioPharma 

Academic Experience 

Lecturer in the Department of Medical Education at the Faculty of Medical and Health Sciences at Tel Aviv University 

JIMS Journal Club - Instructor for students. 

Guidance of Dr. Aviv Berkovich M.D in basic science: cfDNA NGS for identification ofprimary and acquired resistance in patients with Lung Cancer and EGFR mutations. 

TASMC, Israel in collaboration with The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, NY USA 

Training team for oncology residents, TASMC, Israel 

Mentor for new intern, TASMC, Israel 

Tutor for medical students in oncology clerkships, Tel-Aviv University, Israel 

Honors 

Outstanding teacher in the faculty of medicine, Tel-Aviv University, Israel

 Outstanding teacher in the faculty of medicine, Tel-Aviv University, Israel 

Sign of honor for reserve medical personnel for the battle in Lebanon, IDF

Completion of residency final examination (shlav Beit) with honors 

Israeli society for clinical oncology and radiation therapy (ISCORT) 17 research grant competition winner 

Affiliations 

Israeli Medical Association (IMA) 

Israeli Society for Clinical Oncology and Radiation Therapy (ISCORT) 

The Israeli Lung Cancer Group (ILCG) 

European Society of Medical Oncology (ESMO) 

International Association for the Study of Lung Cancer (IASLC) 

The International Society of Liquid Biopsy (ISLB) 

The Israeli Society for Health-Tech 

Boards 

Co-founder, board member and treasurer of the Israeli Acute Oncology Society 

Clinical Research Association Board of Directors on behalf of the Israeli Lung Cancer Group 

Member of the Trustees of Oncology Innovation, TASMC, Israel 

Doctor of Medical Service IDF 

Areas of interest 

Thoracic malignancies, 

early to late phase clinical trials, 

intra-tumoral injections, 

comprehensive genomic profiling of tumors, 

liquid biopsies: cfDNA, TCR rep-seq and epi-Genetics; 

cell therapy

Dr. Rahib Hasanov is a medical oncologist. He graduated from Istanbul University Cerrahpaşa Faculty of Medicine (1999–2005). He completed an internal medicine residency (2009–2013) and a medical oncology fellowship at Marmara University (2015–2018). He also completed an observership at Houston Methodist Hospital (2006–2007).

He focuses on personalized oncology. His treatments include immunotherapy, targeted therapy, and novel agents. His clinical interests include gastrointestinal, breast, lung, and genitourinary cancers.

He attends national and international conferences. He welcomes patients from Turkey, Azerbaijan, Montenegro, Georgia, Uzbekistan, the Middle East, Europe, and the United States.

Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

Pediatric surgeon

Dr. Mehmet Doğu Canoğlu is a radiation oncologist. He graduated from Kocaeli University Faculty of Medicine. He completed his residency in radiation oncology at Kocaeli University from 2006 to 2012.

He completed his compulsory service at Diyarbakır Training and Research Hospital. He then worked at Bağcılar Training and Research Hospital and at Medipol Mega University Hospital from 2015 to 2017. Since 2017, he has been a radiation oncologist at Anadolu Medical Center.

Prof. Dr. M. Emre Üstündağ is a Professor of Otorhinolaryngology–Head and Neck Surgery at Anadolu Medical Center in Gebze. He has been a professor at Kocaeli University since 2006. He completed his MD and ENT residency at Istanbul University between 1983 and 1995. He has worked at Istanbul and Kocaeli universities and at Acıbadem hospitals. He has also maintained a private practice since 2006.

Clinical focus: head and neck oncology and surgery; rhinology and rhinoplasty; laryngology; septoplasty; sleep apnea surgery.

He completed international training in Ireland (Ardkeen). In Germany, he trained in Tübingen; Freiburg (otology, 4 months); and Regensburg (rhinology, 4 months). In the USA, he trained at Stanford in laryngology and sleep apnea (4 months). He has 47 international articles and 788 citations (Google Scholar, Jan 2026). He is a member of the Turkish ORL-HNS, the Istanbul University ENT Association, and the German ORL-HNS.

Dr. Francesc Cobo Valien graduated from the Faculty of Medicine of the University of Barcelona in 1990.

He received his specialization in oncohematology at the Hospital Clínic de Barcelona in 1995. He combined medical practice and research activities in the period 1996-2002.

He received his Doctor of Medicine degree from the University of Barcelona in 2002.

Dr. Kobo continues his research and has been awarded grants:

•Interdepartmental Commission for Innovation of the Generalitat de Catalunya

•Scholarship Fund Universitaria Agustí Pedro i Pons

•Farreras Valentí & Schering Plough School of Hematology Scholarship

•Award for the best report at the Council of the Spanish Hematology Association

•Grant from the Catalan Society of Hematology

Specialization:

•Lymphoma

•Acute leukemia

•Chronic leukemia

•Autoimmune pancytopenia

Dr. Balaña received her medical degree from the Central University of Barcelona and completed her residency in medical oncology at one of the best public hospitals in Spain, Vall d'Hebrón Hospital.

She was a leading specialist in the treatment of brain tumors at the Institute of Oncology of Catalonia, a founding member and current president of the Spanish Neuro oncology Research Group (GEINO), and a member of the scientific committee of the European Association for Neuro-Oncology.

He is the recipient of prestigious research grants in the field of brain tumors.

Dr. Balaña is also a member of the European Society of Medical Oncology and the author of modern European protocols for the treatment of brain tumors, as well as the protocols of the Spanish Society of Medical Oncology (SEOM).

Dr. Balaña has published over 400 articles, books and scientific papers at national and international conferences.

He is the author of articles in prestigious scientific publications such as:

Lancet Oncology;

Nature Reviews in Clinical Oncology;

Clinical Cancer Research and others.

Dr. Lana Bijelic is a board-certified oncological surgeon. She specializes in peritoneal carcinomatosis. Since 2019, she has been part of the Carcinomatosis Surgical Group at the Teknon Oncology Institute. She trained under Prof. Paul Sugarbaker at Washington Hospital Center and brings strong expertise to her team.

Dr. Bijelic has worked as Research Director at Inova Fairfax Hospital. She has also been an associate professor at Virginia Commonwealth University and Georgetown University. She is an active member of the American College of Surgeons and the Society of Surgical Oncology.

Throughout her career, Dr. Bijelic has received many academic awards, including several Surgical Excellence Awards and top prizes in research. She is known for her leadership and important contributions to surgical oncology.

One of the best cancer specialists in Europe, educator, and cancer researcher, President of the Central European Cooperative Oncology Group (CECOG).
Has published over 600 scientific papers on cancer treatment.

Dr. Irina Stepfansky is an oncologist and internal medicine specialist at Sourasky Medical Center. She has more than 25 years of clinical experience. Since 2015, she has directed the Oncology Hospitalization department. Dr. Stepfansky earned her medical degree from Grodno University in Belarus. She completed advanced oncology training at Tel Aviv Medical Center.

Dr. Stepfansky has been licensed in Israel since 2000. She has led and participated in many phase I-III oncology clinical trials. Her work has helped improve cancer care and patient outcomes. She is recognized for her expertise in both internal medicine and oncology. Dr. Stepfansky has a strong record in research and clinical leadership.

Dr. Michael Shapira is a specialist in Bone Marrow Transplantation with over 20 years of experience. He graduated from the Hebrew University Medical School in 1999. He completed his training in internal medicine at Hadassah Medical Center.

Dr. Shapira is a senior physician in the Bone Marrow Transplantation department at Hadassah. He has played a key role in many successful transplants and has helped maintain high patient survival rates. He is known for his clinical skills and commitment to improving transplantation medicine.

Dr. Dror Levin is a senior pediatrician and director of the blood disorder and bone cancer (sarcoma) treatment departments at Children's Hospital "Dana" and Medical Center "Sourasky" respectively. He is a specialist in pediatric medicine, hematology, and oncology, with additional experience studying abroad at the Rizzoli Orthopaedic Institute in Italy.

Coping with gastrointestinal and lung cancer without chemotherapy. Specialists at the Tel Aviv Sourasky Clinic (Ichilov) use an ultra-modern innovative method to combat neuroendocrine tumors. It is based on radionuclide therapy with the radioisotope Lutetium 177 (Lutetium-177). This innovation is a real breakthrough in oncotherapy, because in recent decades the number of cases of this type of cancer has been rapidly growing.

This method is completely new in the world. Today it exists only in Israel, Germany and Sweden.

Its essence is in the use of a new radiopharmaceutical - Lutetium 177 PRRT. The drug is administered intravenously at intervals of 7-8 weeks. With the help of Lutetium, cancer cells are destroyed selectively, without affecting healthy tissues of the body. That is, this method of treatment can literally be called "local radiation therapy". In addition, the drug does not have a toxic effect on the bone marrow and kidneys, destroying the tumor from the inside.

In addition, the use of this method allows patients to avoid severe side effects of chemotherapy, such as vomiting, nausea, pain, alopecia, weakness. It is also important that the treatment is carried out by a special group of medical specialists. Among them: leading doctors, nurses and medical physicists!

All of them work under the supervision of Dr. Inna Ospovat, a leading specialist in the nuclear therapy department at the Ichilov Clinic.

Education

2000-1994 Faculty of Medicine in Vitebsk, Belarus.

Specialization

2003 - 2011 - specialization in oncology and radiation therapy at the Hadassah University Hospital in Jerusalem.

Recognized experience

Oncology and radiation therapy

Additional education

2015 - PMH University Hospital (Totonto) Childhood irradiation and head and neck tumors

Attending conferences

About 10 presentations at medical conferences

Trade union membership

• Israel Society of Clinical Oncology and Radiotherapy ISCORT
• American Association of Radiation Therapy ASTRO
• Israel Head and Neck Oncology Association
• Areas of special interest and activities
• Radiation therapy in children
• Radiobiological treatment PRBT
• Radiation therapy for gastrointestinal tumors
• Treatment of head and neck tumors and skin tumors